TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04156776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Isolated Stretching
Description: The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
Study: NCT03906045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF-MDI
Description: Budesonide, Glycopyrronium and Formoterol Fumarate.
Study: NCT03168308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine w/ Glycopyrrolate
Description: Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
Study: NCT02045576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sleep position trainer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral Appliance Therapy
Study: NCT02951156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Investigational fully human anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Investigational, fully human IgG2 CD 137/4-1BB agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Investigational, fully human IgG2 CD 137/4-1BB agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Investigational, fully human IgG2 CD 137/4-1BB agonist

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20-directed cytolytic antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20-directed cytolytic antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: CD20-directed cytolytic antibody
Study: NCT01884207

Intervention type: OTHER
Intervention: MRI
Study: NCT02951156

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: CD20-directed cytolytic antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Antimetabolite antineoplastic agent and demethylation agent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Antimetabolite antineoplastic agent and demethylation agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Alkylating drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Alkylating drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Alkylating drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Nucleoside analogue
Study: NCT04052594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3475766 - SC
Description: Administered SC
Study: NCT02951156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Platinum-based drug
Study: NCT03386942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab Ecteribulin
Description: Part 1: farletuzumab ecteribulin intravenous (IV) infusion administered every 3 weeks starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: farletuzumab ecteribulin administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
Study: NCT02755324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: male Schistosoma mansoni cercariae
Description: Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
Study: NCT03582020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menu plans
Description: menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: menu plans
Description: menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menu plans
Description: menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menu plans
Description: menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
Study: NCT02245074

Intervention type: OTHER
Group type: OTHER
Intervention: Sputum induction
Description: The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.

Intervention type: OTHER
Group type: OTHER
Intervention: Sputum induction
Description: The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.

Intervention type: OTHER
Group type: OTHER
Intervention: Sputum induction
Description: The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
Study: NCT00277433

Intervention type: OTHER
Intervention: Buccal Swab
Description: collection of buccal swab

Intervention type: OTHER
Intervention: Buccal Swab
Description: collection of buccal swab
Study: NCT01408979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 12 hours
Description: Magnesium sulfate, 1g/h, (10% solution), for 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate 24 hours
Description: Magnesium sulfate, 1g/h, (10% solution), for 24 hours
Study: NCT01946373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine
Study: NCT05476341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab injection
Description: Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab injection（Avastin）
Description: Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor
Study: NCT00944450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate anhydrous formulation
Description: Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin phosphate monohydrate form
Description: Single dose sitagliptin 100 mg tablets \[monohydrate Final Market Image (FMI) form\] in one of two treatment periods.
Study: NCT01467947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection
Description: Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
Study: NCT01718652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
Study: NCT05546047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar Gel 80 UNT/ML Injectable Solution
Description: Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar Gel 80 UNT/ML Injectable Solution
Description: Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
Study: NCT01136850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloroquine, sulphadoxine pyrimethamine, LLIN
Description: \> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~\< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin, sulphadoxine pyrimethamine, LLIN
Description: sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation.
Study: NCT02474992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic
Description: Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
Study: NCT04214912

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Personalized Survivor Care Plan (PSCP)
Description: Based the above literature review and our previous 10 years' efforts in OC patients' distress and care needs survey, we categorize OC patients' distress and needs into 6 major dimensions (1) symptoms management and dysfunction prevention (different kind of symptom, such as swallowing difficulty, eating difficulty, speaking difficulty, difficulty in opening mouth/trismus, shoulder dysfunction, mucositis, pain, fatigue, etc), (2) enhancing physical function (exercise skills, types for major parts of muscle training), (3) Confronting and dealing with psychological distress (fear, anxiety, depression, uncertainty), (4) nutrition assessment and counseling, (5) Social connection and RTW counseling (attitudes and skills for returning to work), and (6) overall needs assessment and supports.
Study: NCT02827500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Description: Active Comparator: ivabradine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Placebo Comparator: usual care
Study: NCT01241760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
Study: NCT02303821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Study: NCT01241760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: 750 mg (2 oral tablets) every 8 hours for 12 weeks
Study: NCT00913614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplivanserin (SR46349)
Description: Oral administration
Study: NCT01989702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fermented blueberry drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sachets with probiotic bacterial powder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sachets with placebo powder

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sachets with placebo powder
Study: NCT01846559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: E.coli Endotoxin Day 7 - 2 ng/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: E.coli Endotoxin Day 7 - 2 ng/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: E.coli Endotoxin Day 7 - 2 ng/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
Study: NCT04615325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303359
Description: RO730359 will be administered as a single intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303359
Description: RO730359 will be administered as a single intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303359
Description: RO730359 will be administered as a single intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303359
Description: RO730359 will be administered as a single intravitreal injection.
Study: NCT03112304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATCH-ADTC
Description: MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATCH-ADTC
Description: MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita \& Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAC
Description: TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TRAC
Description: TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard.
Study: NCT03823950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Begin G-CSF 72 hours following chemotherapy
Study: NCT03177096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peds QL questionnaire and diabetes modulate
Description: Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO-5 questionnaire
Description: WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Felt questionnaire
Description: Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
Study: NCT03845972

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSFTB
Description: Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
Study: NCT01739803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Contract
Description: Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
Study: NCT01869413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.